U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07700667) titled 'SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma' on July 08.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into three parts: the safety run-in phase, randomized enrollment phase and cohort expansion phase.
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
DRUG: SKB500
SKB500 will be administered as an intravenous infusion(IV), every 3 weeks on Day 1 of each 21-day cycle.
DRUG...